Table 2: Functional tests, gait parameters, and drug treatments a.

All patients ( )Nonfallers ( )Fallers ( )Testb value

Tinetti
 Balance10.9 (5.7)13.4 (3.9)7.1 (6.0)1<0.001
 Gait8.6 (4,6)10.3 (3.2)5.8 (5.2)1<0.001
 Total19.5 (10.2)23.7 (7.0)12.9 (11.0)1<0.001
Timed up and go (s)11.4 (8.0)10.7 (7.9)13.1 (8.1)10.004
Velocity (m/s)1.17 (0.31)1.19 (0.30)1.10 (0.32)10.293
Step length (m)0.77 (0.20)0.79 (0,24)0.69 (0.22)10.093
Cadence (steps/s)1.55 (0.70)1.52 (0.23)1.61 (0.41)10.253
Levodopa use ( , %)139 (86.8)84 (85.7)55 (88.7)20.639
Levodopa dose (mg/d)557.8 (254.1)504.1 (208.3)638.7 (295.8)10.005
Dopamine agonist use ( , %)98 (61.2)58 (59.2)40 (64.5)20.511
MAOB-I use ( , %)49 (30.6)29 (29.5)20 (32.2)20.728
COMT-I use ( , %)25 (15.6)10 (10.2)15 (24.2)20.025
Amantadine use ( , %)13 (8,1)5 (5.1)8 (12.9)20.134
Anticholinergic use ( , %)2 (1.2)2 (2.0)0
Polytherapy ( , %)83 (51.8)49 (50.0)34 (54.8)20.649
Benzodiazepine use ( , %)22 (13.7)12 (12.2)10 (16.1)20.490
Antidepressant use ( , %)18 (11.2)11 (11.2)7 (11.3)21.000
Neuroleptic use ( , %)8 (5.0)1 (1.0)7 (11.3)20.006
Cholinesterase inhibitor use ( , %)7 (4.3)07 (11.3)20.001

Abbreviations. MAOBI: inhibitor of monoamine oxidase B; COMTI: inhibitor of catechol-O-methyl transferase.
aData are mean(SD), absolute numbers, or percentage.
bTest 1 = independent samples -test; test test.